

62
(amended) 45. [A] The method [for inhibiting Hepatitis B virus (HBV) infection or replication comprising administering a compound that] of Claim 39 wherein the compound administered decreases the activity of upstream activators of Src kinase as determined by an *in vitro* assay comprising;

- a) contacting a cell expressing HBx with the compound;
- b) measuring the activity of a component of the upstream activation pathway of Src;
- c) comparing the measured activity to that of a cell expressing HBx not contacted with the compound; and
- d) determining whether the compound reduces the activity of the component of the upstream activation pathway of Src.

(amended) 46. [A] The method [for inhibiting Hepatitis B virus (HBV) infection or replication comprising administering a compound that] of Claim 39 wherein the compound administered decreases the interaction of cellular protein upstream activators of Src kinase with viral proteins as determined by an *in vitro* assay comprising;

- a) contacting a cell expressing HBx with the compound;
- b) measuring the activity of a component of the upstream activation pathway of Src;
- c) comparing the measured activity to that of a cell expressing HBx not contacted with the compound; and
- d) determining whether the compound reduces the activity of the component of the upstream activation pathway of Src.